Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2018-12-31
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There is now new types of treatments (antibody drugs) which are licensed to manage severe asthma such as Anti-IL5. There is evidence Anti-IL5 and other similar antibody drugs are effective at reducing asthma exacerbations and reduce the need for oral corticosteroids for those that have severe asthma.
However, some patients respond poorly to Anti-IL5 and the investigators would like to find out why this happens. It is hoped that the investigators can identify the mechanism of poor treatment response to Anti-IL5. It is also hoped that the investigators can understand why symptoms worsen to the point of requiring antibiotics and/or steroids (also known as an exacerbation) for those prescribed Anti-IL5.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Severe asthma
Untreated by anti-IL5 treatment for severe asthma at point of recruitment. To be prescribed anti-IL5 as part of their treatment following consent. Note: Anti-IL5 treatment is prescribed as per agreed multidisciplinary team meeting, outside of the decision to enrol the patient on the study, and is administered by the clinical team as part of the patient's clinical care outside of the research study.
Anti-IL5 Antibody
Asthma group: Anti-IL5 treatment Control group: No biologic.
Bronchoscopy
Optional for both arms
Healthy control
Control group without respiratory condition
Bronchoscopy
Optional for both arms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-IL5 Antibody
Asthma group: Anti-IL5 treatment Control group: No biologic.
Bronchoscopy
Optional for both arms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give informed consent
* All patients identified as being suitable for anti-IL5 therapy by the asthma MDT will be considered for study enrolment.
This assessment by the MDT for participants to be eligible includes:
* A measure of compliance with current asthma medication,
* Confirmation of asthma diagnosis
* Suitability for anti-IL5 therapy based on blood eosinophil counts,
* Asthma exacerbation rates
* Prednisolone dose.
* Confirmation of treatment requires at least two asthma specialists to agree that this is the correct course of action
* Patients must first demonstrate over 75% compliance with inhaled and/or oral corticosteroid therapy
The asthma MDT and difficult asthma clinic normally assess patients between 18-80 years so only patients in this age range will be approached.
All patients will be able to give informed consent for study participation.
* Aged between 18-80 years old.
* Able to give informed consent
Exclusion Criteria
* Pregnancy
* Underlying respiratory conditions
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Nottingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nottingham Respiratory BRU
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18048
Identifier Type: -
Identifier Source: org_study_id